胃癌患者血清PGⅠ、PGⅡ、G-17表达水平及意义

The expression and significance of serum levels of PGⅠ, PGⅡ and G-17 in gastric cancer

目的探讨胃癌患者血清胃蛋白酶原(PG I、PGⅡ)、胃泌素-17(gastrin, G-17)表达水平及意义。方法选取2015年10月至2018年7月河南省濮阳市人民医院收治的行胃镜检查的胃部不适患者297例,根据胃黏膜病理结果,分为健康对照组(n=42)、非萎缩性胃炎组(n=53)、萎缩性胃炎组(n=56)、胃溃疡组(n=64)和胃癌组(n=82)。采用酶联免疫吸附法检测各组血清PGⅠ、PGⅡ、G-17,计算胃蛋白酶原比值(pepsinogen ratio, PGR),即PGⅠ/PGⅡ,比较各组间差异。结果 PGⅠ水平在各组间差异有统计学意义(F=28.547,P=0.001),其中胃癌组PG I水平最低,其次是萎缩性胃炎组。PGⅡ水平在各组间差异有统计学意义(F=4.276,P=0.006),其中萎缩性胃炎组水平最低,胃溃疡组水平最高。PGR在各组间差异有统计学意义(F=10.063,P=0.001),其中胃癌组水平最低,其次是萎缩性胃炎组。G-17水平在各组间差异有统计学意义(F=5.829,P=0.001),其中胃癌组水平最高,其次是萎缩性胃炎组。早期胃癌与中晚期胃癌在PGⅠ、G-17、PGR上的差异均有统计学意义(P<0.05),早期胃癌组的PG I水平更高,G-17水平更低,PGR更高。胃癌组PGⅠ与PGR呈正相关(r=0.813,P<0.05),G-17与PGR呈负相关(r=-0.738,P<0.05);G-17与PG I呈负相关(r=-0.767,P<0.05),PGⅡ与PGR呈负相关(r=-0.302,P<0.05)。结论血清PGⅠ、G-17及PGⅠ/PGⅡ比值与胃癌的发生发展有一定相关性,这些指标的变化可用于胃癌筛查及评估。

Objective To investigate the expression and significance of serum levels of PGⅠ, PGⅡ and G-17 in gastric cancer. Methods A total of 297 outpatients and inpatients who underwent gastroscopy in our hospital from October 2015 to July 2018 were collected. According to the pathological results of gastric mucosa, the subjects were divided into healthy control group, non-atrophic gastritis group, atrophic gastritis group, gastric ulcer group and gastric cancer group. Serum PGⅠ, PGⅡ and G-17 were detected by enzyme linked immunosorbent assay, and PGR(PGⅠ/PGⅡ) was calculated to compare the differences among groups. Results The level of PGⅠ was significantly different among the groups(F = 28.547, P =0.001). The lowest level of PGⅠ was found in gastric cancer group, followed by atrophic gastritis group. There was significant difference in PGⅡ level among the groups(F = 4.276, P = 0.006), among which atrophic gastritis group had the lowest level and gastric ulcer group had the highest level. There was significant difference in PGR among the groups(F = 10.063,P = 0.001), among which gastric cancer group had the lowest level, followed by atrophic gastritis group. There was significant difference in G-17 level among the study groups(F = 5.829, P = 0.001), among which gastric cancer group had the highest level, followed by atrophic gastritis group. There were significant differences in PGⅠ, G-17 and PGR between early gastric cancer and advanced gastric cancer(all P < 0.05). The level of PGⅠ and PGR in early gastric cancer group was higher, the level of G-17 was lower was higher. In gastric cancer group, PG I was positively correlated with PGR(r = 0.813, P<0.05), G-17 was negatively correlated with PGR(r =-0.738, P<0.05), G-17 was negatively correlated with PG I(r =-0.767, P<0.05), and PGⅡ was negatively correlated with PGR(r =-0.302, P<0.05). Conclusions Serum PGⅠ, G-17 and PGR are correlated with the occurrence and development of gastric cancer. These changes can be used for screening and evaluation of gastric cancer.